Stryker is positioned for success in robot sales and market gains, thanks to its robust portfolio and in-demand robotic surgery platform, according to an analysis by Zacks Equity Research.
Five takeaways:
1. Stryker has recently seen a "significant rise" in new installations of its Mako Total Knee platform.
2. The company anticipates solid robot sales in 2019 at hospitals, as well as heightened surgeon interest in orthopedic robotic programs.
3. Stryker management is hopeful about gaining regulatory approvals for the company's total knee products in China and Japan this year.
4. The wide range of products in Stryker's portfolio is expected to shield the company from any significant sales shortfall during economic downturns.
5. Stryker's long-term earnings growth rate is promising, at 10 percent.